Clinical Trials Logo

Contraception clinical trials

View clinical trials related to Contraception.

Filter by:

NCT ID: NCT01941134 Withdrawn - Contraception Clinical Trials

Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery

Start date: April 2013
Phase: Phase 4
Study type: Interventional

This study will attempt to determine whether having gastric bypass surgery changes the way that the gut absorbs hormones from birth control pills. It is believed that, because gastric bypass surgery causes malabsorption of nutrients and some medications, the levels of birth control hormones after the surgery will be lower than in women before they have the surgery. The investigators will ask several women to take a pack of birth control pills before having bypass surgery, and then another pack several months after surgery. The investigators will measure hormone levels in the blood. The investigators will also measure outcomes that may tell us how well the birth control pills are working, such as ultrasounds of the uterus and ovaries, and examination of the cervix.

NCT ID: NCT01936454 Completed - Contraception Clinical Trials

Contraceptive Effectiveness of Sino-implant (II) in China

Start date: July 2013
Phase: N/A
Study type: Observational

A cohort study to Evaluate the contraceptive effectiveness of Sino-implant (II) during the 3rd and 4th years of use in Chinese women

NCT ID: NCT01930994 Withdrawn - Contraception Clinical Trials

Kenya Sino-implant (II) PK Study

Start date: September 2013
Phase: N/A
Study type: Observational

A cross-sectional study to compare pharmacokinetics of Sino-implant (II) during four years of used and Jadelle during five years of use by Kenyan women.

NCT ID: NCT01915069 Completed - Contraception Clinical Trials

Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary

Start date: July 2013
Phase: Phase 2
Study type: Interventional

Combined oral contraceptive pills (COCs) are the most commonly used hormonal form of birth control in the United States with at least 87% of women of reproductive age reporting oral contraceptive use at some point in their lives (9). Despite their frequent use, the six and twelve month discontinuation rates for oral contraceptive pills are 31 and 47 % respectively (17), with common reasons for discontinuation attributed to the side effects of abnormal bleeding, headache, and weight gain. Additionally, COCs are contraindicated in certain groups of women as outlined by The Centers for Disease Control Medical Eligibility Criteria (11). Given the high prevalence of oral contraceptive users who commonly discontinue use secondary to side effects or who are not eligible for use as a result of underlying health conditions, the development of novel oral non-hormonal methods that are equally effective at pregnancy prevention are warranted. This current study aims to evaluate the effect of an FDA approved drug, Cilostazol, on human oocyte maturation. Such a study has not been conducted to date. If Cilostazol demonstrates an ability in humans to affect resumption of meiosis, then this non-hormonal agent could be uses as a possible contraceptive agent in the future. This knowledge would have profound reproductive health implications. The investigators propose that women undergoing treatment with the FDA approved dose of 100mg PO every 12 hours of Cilostazol will demonstrate an impairment of egg maturation in comparison to paired historic controls following ovarian follicle stimulation.

NCT ID: NCT01902485 Completed - Contraception Clinical Trials

Study of Immediate Start of Progestin Contraceptives in Medical Abortion

Quickstart
Start date: July 2013
Phase: Phase 4
Study type: Interventional

This study will compare immediate to post-abortion start of two progestin-based contraceptives (DMPA and etonorgestrel implants) among women having first trimester medical abortion who wish to use that method for post-abortion contraception.

NCT ID: NCT01902264 Completed - Contraception Clinical Trials

Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception

Start date: August 2013
Phase: Phase 3
Study type: Interventional

The objective of this study is to compare the red blood cell (RBC) and plasma concentrations of folate in subjects treated with drospirenone (DRSP)/ethinyl estradiol (EE) plus levomefolate calcium (L-5-MTHF) at 24 weeks with respect to basal determination. Increased intake of folic acid (synthetic form of the naturally occurring B-vitamin) before and in the first few weeks of pregnancy has been shown to reduce certain types of birth defects. This is important for women who may become pregnant following discontinuation of oral contraception. Information about any side effects that may occur will also be collected.

NCT ID: NCT01893021 Completed - Contraception Clinical Trials

Family Planning Knowledge, Attitudes, and Practices of Postpartum Malawian Women

Start date: May 2013
Phase: N/A
Study type: Observational

The purpose of this study is to understand the family planning needs and practices of postpartum Malawian women, with a focus on long-acting reversible contraception (LARC). Hypotheses: 1. Postpartum women who are older, who have a history of unintended pregnancy, who do not desire another child within 2 years, and who were counseled about LARC during their pregnancy are more likely to have interest in using LARC. 2. Postpartum women who are older are more likely to be aware of LARC methods. 3. HIV+ postpartum Malawian women will have similar knowledge about LARC as postpartum Malawian women who are HIV-.

NCT ID: NCT01873170 Completed - HIV Clinical Trials

Quantification of Immune Cells in Women Using Contraception (CHIC II)

CHIC-II
Start date: August 2013
Phase:
Study type: Observational

This study is being done to understand if using birth control causes changes in the immune cells within the reproductive tract (including the cervix and the lining of the uterus) of healthy women. Immune cells are important because they help prevent infections from starting and help fight infections that have started. Immune cells are also the type of cells that HIV (human immunodeficiency virus) infects so understanding more about them will help to better understand how to prevent the spread of HIV. Immune cells will be studied from the reproductive tract of women who want to start using one of the following contraceptives: an oral contraceptive pill (COC), Depo-Provera (DMPA), the levonorgestrel IUD (Mirena®), the copper IUD (ParaGard®), or the etonogestrel subdermal implant (Nexplanon®).Immune cells will also be studied from the reproductive tract of women who are not using birth control and who are not at risk of pregnancy for comparison.

NCT ID: NCT01861886 Completed - Contraception Clinical Trials

The Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women

Start date: January 31, 2013
Phase: N/A
Study type: Interventional

To evaluate the safety and long-term (approximately one year) effectiveness of the Essure System for Permanent Birth Control ESS505 device in preventing pregnancy.

NCT ID: NCT01855620 Completed - Obesity Clinical Trials

The Effect of Body Mass Index on Etonogestrel Hormone Levels in Women Using the Single-rod Contraceptive Implant

Eto BMI
Start date: December 2012
Phase: N/A
Study type: Observational

Two-thirds of young women in the United States are overweight or obese. This excess weight may affect how their body metabolizes drugs such as different birth control methods. There is a not a lot of research about how excess weight could affect the hormone levels of the contraceptive implant. Methods like the implant contain only progesterone, which is a hormone that does not increase a woman's risk of blood clot. These methods would be preferred for overweight and obese women because excess weight also increases a woman's risk of blood clot. The investigators propose a study comparing blood hormone levels of women using the implant for at least twelve months and in all weight categories. The investigators hope to show that all women, regardless of weight, will have hormone levels high enough to prevent pregnancy.